CAR-T immunotherapy has proved a powerful treatment option for patients with certain advanced blood cancers — but it can be very dangerous as well, causing severe and sometimes deadly inflammation in the brain.
Now, researchers are a step closer to figuring out why — and to identifying those patients most likely to suffer severe reactions.
About the Author Reprints
